A review of nelfinavir for the treatment of HIV infection.

Abstract

Nelfinavir (NFV) is a protease inhibitor that has been widely used for several years for the treatment of HIV infection. This has led to extensive experience with NFV-containing regimens, in which the drug has shown prolonged viral suppression, good tolerability and a unique resistance profile. In recent years, several antiretroviral drugs with some advantages over NFV have been developed. Nevertheless, NFV has favourable characteristics that make it a suitable antiretroviral compound for many HIV-infected patients. It can be used in patients who do not tolerate ritonavir even at low doses, and it is well tolerated in pregnant women, has a low-grade interaction with methadone and may be well tolerated in hepatitis C virus-co-infected patients. In addition, its new simplified posology may contribute to improved adherence.

• Authors: Montserrat Olmo, Daniel Podzamczer
• Journal: Expert opinion on drug metabolism & toxicology (Expert Opin Drug Metab Toxicol) Vol. 2 Issue 2 Pg. 285-300 (Apr 2006) ISSN: 1742-5255 [Print] England
• PMID: 16866614 (Publication Type: Journal Article, Review)

Chemical References

• Protease Inhibitors
• Nelfinavir

Topics

• Female
• HIV Infections (drug therapy)
• Humans
• Molecular Structure
• Nelfinavir (chemistry, therapeutic use)
• Pregnancy
• Pregnancy Complications, Infectious (drug therapy, virology)
• Protease Inhibitors (chemistry, therapeutic use)
• Treatment Outcome